| Literature DB >> 22566858 |
Lars Rønn Olsen1, Guang Lan Zhang, Derin B Keskin, Ellis L Reinherz, Vladimir Brusic.
Abstract
Broad coverage of the pathogen population is particularly important when designing CD8+ T-cell epitope vaccines against viral pathogens. Traditional approaches are based on combinations of highly conserved T-cell epitopes. Peptide block entropy analysis is a novel approach for assembling sets of broadly covering antigens. Since T-cell epitopes are recognized as peptides rather than individual residues, this method is based on calculating the information content of blocks of peptides from a multiple sequence alignment of homologous proteins rather than using the information content of individual residues. The block entropy analysis provides broad coverage of variant antigens. We applied the block entropy analysis method to the proteomes of the four serotypes of dengue virus (DENV) and found 1,551 blocks of 9-mer peptides, which cover 99% of available sequences with five or fewer unique peptides. In contrast, the benchmark study by Khan et al. (2008) resulted in 165 conserved 9-mer peptides. Many of the conserved blocks are located consecutively in the proteins. Connecting these blocks resulted in 78 conserved regions. Of the 1551 blocks of 9-mer peptides 110 comprised predicted HLA binder sets. In total, 457 subunit peptides that encompass the diversity of all sequenced DENV strains of which 333 are T-cell epitope candidates.Entities:
Keywords: antigenic diversity; epitope-based vaccines; immunoinformatics; polyvalent vaccines; reverse vaccinology; vaccine informatics
Year: 2011 PMID: 22566858 PMCID: PMC3341948 DOI: 10.3389/fimmu.2011.00069
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Sequence data used in this analysis.
| Protein | DENV serotype | Total | |||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| anC | 1235 | 872 | 739 | 189 | 3035 |
| prM | 1235 | 933 | 742 | 194 | 3104 |
| E | 1759 | 1487 | 1011 | 409 | 4666 |
| NS1 | 1226 | 912 | 595 | 106 | 2839 |
| NS2A | 1241 | 839 | 565 | 105 | 2750 |
| NS2B | 1241 | 838 | 565 | 105 | 2749 |
| NS3 | 1214 | 838 | 565 | 105 | 2722 |
| NS4A | 1214 | 837 | 566 | 105 | 2722 |
| 2K | 1214 | 838 | 566 | 105 | 2723 |
| NS4B | 1213 | 838 | 566 | 105 | 2722 |
| NS5 | 1209 | 835 | 566 | 105 | 2715 |
| Total | 14001 | 10067 | 7046 | 1633 | 32747 |
Figure 1The frequency of the 190 known epitopes sorted from most to least frequent.
The total number of blocks which covers 99% of the sequences with five peptides or less, as well as the relative distribution of numbers of peptides in each block.
| Peptide length | Total number of blocks | Blocks with 99% coverage with ≤5 peptides | Distribution of number of peptides in blocks | ||||
|---|---|---|---|---|---|---|---|
| 1 peptide | 2 peptides | 3 peptides | 4 peptides | 5 peptides | |||
| 8 | 3393 | 1732 | 199 | 355 | 388 | 460 | 330 |
| 9 | 3392 | 1551 | 142 | 319 | 341 | 435 | 314 |
| 10 | 3391 | 1394 | 102 | 278 | 295 | 418 | 301 |
| 11 | 3390 | 1245 | 75 | 228 | 266 | 386 | 290 |
This table is a summary of block of 8, 9, 10, and 11-mer peptides.
Figure 2(A) The number of 9-mer peptides required to cover 99% of a block, for each possible start position in the proteome. (B) The number of 9-mer peptides required to cover 99% of a block, sorted in increasing order.
Figure 3. The black diamonds correspond to blocks in which no peptides are predicted to bind to the HLA. The blue circles indicate that some, but not all, peptides within that block are predicted to be epitopes. The red squares indicate that all peptides within the block are predicted to bind the same HLA type.
Details of the peptides observed in block 388 of the NS3 protein.
| # | Peptide | Frequency | Acc. frequency | Bits | HLA binding (nM) | Serotypes containing peptide (%) |
|---|---|---|---|---|---|---|
| 1 | KTFDTEYQK | 65.03 | 65.03 | 0.84 | A*03:01(59.69); A*11:01(5.41) | DENV1(99.67) DENV3(99.32) |
| 2 | KTFDSEYVK | 28.69 | 93.72 | 0.37 | A*03:01(51.48); A*11:01(7.19) | DENV1(0.08) DENV2(92.64) |
| 3 | KTFDTEYPK | 3.82 | 97.54 | 0.05 | A*03:01(26.17); A*11:01(3.35) | DENV4(100) |
| 4 | KTFDSEYIK | 1.18 | 98.71 | 0.02 | A*03:01(71.55); A*11:01(8.59) | DENV2(4.19) |
| 5 | KTFDTEYTK | 0.29 | 99.01 | 0.00 | A*03:01(37.45); A*11:01(4.65) | DENV2(0.95) |
| 6 | KTFDSEYAK | 0.29 | 99.30 | 0.00 | Not predicted | DENV2(0.95) |
| 7 | KTFDTEYIK | 0.26 | 99.56 | 0.00 | Not predicted | DENV2(0.90) |
| 8 | RTFDTEYQK | 0.11 | 99.67 | 0.00 | Not predicted | DENV1(0.25) |
| 9 | KTFETEYQK | 0.11 | 99.78 | 0.00 | Not predicted | DENV3(0.17) |
| 10 | KTFDAEYVK | 0.07 | 99.85 | 0.00 | Not predicted | DENV2(0.25) |
| 11 | KTFNTEYQK | 0.07 | 99.93 | 0.00 | Not predicted | DENV3(0.34) |
| 12 | KTFDTEYQR | 0.04 | 99.96 | 0.00 | Not predicted | DENV3(0.17) |
| 13 | KTFDFEYIK | 0.04 | 100 | 0.00 | Not predicted | DENV2(0.12) |
Peptide 1 (KTFDTEYQK) is a known ligand for HLA-03, -11, and -31. Furthermore, peptides 2–5 are predicted to have similar binding affinity to peptide 1 for HLA-A3 supertype alleles using MULTIPRED2 (Zhang et al., .
Figure 4(A) Sequence logo plot of the residues in the block starting at position 388 of the MSA of NS3 protein sequences. The sequence logo was generated using WebLogo (http://weblogo.berkeley.edu/). (B) Shows a peptide block logo of the peptides in the same block. The block logo was generated locally using the Block Logo tool. The colors of the amino acids correspond to their chemical properties: polar amino acids (G, S, T, Y, C, Q, and N) are shown in green, basic amino acids (K, R, and H) are shown in blue, acidic amino acids (D and E) are shown in red, and hydrophobic amino acids (A, V, L, I, P, W, F, and M) are shown in black.
Conserved blocks with all peptides are predicted (NetMHC) to have high HLA binding affinity.
| Protein | Block | Class I HLA allele | ||||||
|---|---|---|---|---|---|---|---|---|
| A*02:01 | A*03:01 | A*11:01 | A*24:02 | B*07:02 | B*08:01 | B*15:01 | ||
| anC | 14 | 3 | ||||||
| 22 | 5 | |||||||
| 45 | 4 | |||||||
| 50 | 3 | |||||||
| E | 38 | 4 | ||||||
| 209 | 3 | 3 | ||||||
| 211 | 2 | |||||||
| 237 | 4 | 4 | ||||||
| 258 | 4 | |||||||
| 405 | 3 | |||||||
| NS1 | 33 | 4 | ||||||
| 37 | 4 | |||||||
| 40 | 5 | |||||||
| 161 | 4* | |||||||
| 191 | 2 | |||||||
| 224 | 3 | |||||||
| 251 | 4 | |||||||
| 294 | 2 | 2 | ||||||
| 313 | 2 | |||||||
| NS2B | 2 | 5 | ||||||
| 14 | 5 | 5 | ||||||
| 29 | 3 | |||||||
| 46 | 4 | |||||||
| NS3 | 43 | 3 | ||||||
| 48 | 2 | |||||||
| 95 | 3 | |||||||
| 130 | 2 | |||||||
| 183 | 4 | |||||||
| 204 | 4 | |||||||
| 217 | 2 | |||||||
| 218 | 2 | |||||||
| 234 | 3 | |||||||
| 238 | 3 | |||||||
| 258 | 1 | |||||||
| 259 | 2 | |||||||
| 263 | 2 | |||||||
| 275 | 4 | |||||||
| 280 | 4 | |||||||
| 281 | 3 | |||||||
| 313 | 3 | |||||||
| 357 | 1 | |||||||
| 358 | 5 | |||||||
| 388 | 5 | |||||||
| 421 | 2 | |||||||
| 422 | 2 | |||||||
| 433 | 4 | |||||||
| 441 | 2 | |||||||
| NS3 (cont’d) | 447 | 4 | ||||||
| 507 | 5 | 3 | ||||||
| 528 | 5 | |||||||
| 531 | 2 | |||||||
| 536 | 1 | 1 | ||||||
| 593 | 4 | |||||||
| NS4A | 39 | 5 | ||||||
| 104 | 2 | |||||||
| 108 | 3 | |||||||
| 2K | 5 | 5 | ||||||
| NS4B | 2 | 5 | ||||||
| 14 | 5 | 5 | ||||||
| 29 | 3 | |||||||
| 46 | 4 | |||||||
| NS5 | 52 | 3 | ||||||
| 81 | 1 | |||||||
| 86 | 3 | 3 | ||||||
| 116 | 4 | 4 | ||||||
| 117 | 3 | |||||||
| 181 | 4 | |||||||
| 209 | 1 | |||||||
| 300 | 2 | 2 | 2 | |||||
| 317 | 3 | |||||||
| 318 | 3 | 3 | ||||||
| 325 | 2 | |||||||
| 340 | 3 | |||||||
| 346 | 1 | |||||||
| 393 | 5 | |||||||
| 449 | 1 | |||||||
| 453 | 1 | |||||||
| 460 | 2 | |||||||
| 472 | 1 | |||||||
| 475 | 2 | |||||||
| 477 | 2 | 2 | ||||||
| 489 | 2 | |||||||
| 490 | 3 | |||||||
| 570 | 2 | |||||||
| 587 | 4 | |||||||
| 679 | 3* | 5 | ||||||
| 757 | 5 | |||||||
| 759 | 4 | |||||||
| 760 | 4 | 4 | 4 | |||||
| 765 | 1 | |||||||
| 767 | 1 | |||||||
| 772 | 3 | |||||||
| 849 | 3 | |||||||
| 850 | 3 | |||||||
The number in the cells corresponds to the number of peptides needed to cover 99% of the block in which it is found. For the numbers marked with an asterisks (*), the least predominant peptide(s) were not predicted to be an MHC binder, but the remaining peptides cover at least 95%.
The ratio of conservation to size of each DENV protein is shown.
| Protein | Fraction of proteome (%) | Immuno-functionally conserved blocks (%) | Immuno-functional conservation: size ratio |
|---|---|---|---|
| anC | 3.36 | 3.64 | 1.08 |
| prM | 4.89 | 0.00 | 0.00 |
| E | 14.59 | 7.27 | 0.50 |
| NS1 | 10.38 | 9.09 | 0.88 |
| NS2A | 6.43 | 0.00 | 0.00 |
| NS2B | 3.83 | 4.55 | 1.19 |
| NS3 | 18.25 | 29.09 | 1.59 |
| NS4A | 3.74 | 2.73 | 0.73 |
| 2K | 0.68 | 0.91 | 1.34 |
| NS4B | 7.34 | 4.55 | 0.62 |
| NS5 | 26.50 | 38.18 | 1.44 |
The conservation to size ratio was calculated by dividing the number of blocks predicted to be immuno-functionally conserved, divided by the relative size (in %) of each protein.
Extended block sequences for string 1.
| Extended block ID | Protein | Position | Sequence |
|---|---|---|---|
| 1,1 | anC | 9–69 | PPFNMLKRERNRVSTGSQLAKRFSKGLFSGQGPMKLVMAFIAFLRFLAIPPTAGILKRWG |
| 1,2 | anC | 81–91 | GFRKEIGRML |
| 1,3 | anC | 113–127 | FHLTTRNGEPHMIV |
| 1,4 | prM | 15–27 | QERGKSLLFKTA |
| 1,5 | prM | 30–47 | NMCTLIAMDLGELCEDT |
| 1,6 | prM | 58–79 | EPEDIDCWCNLTSTWVTYGTC |
| 1,7 | prM | 82–120 | GEHRRDKRSVALVPHVGMGLETRTETWMSSEGAWKHAQ |
| 1,8 | prM | 121–132 | VETWALRHPGF |
| 1,9 | prM | 165–213 | MRCVGVGNRDFVEGLSGATWVDVVLEHGSCVTTMAKNKPTLDFELIKT |
| 1,10 | E | 67–79 | TTDSRCPTQGEA |
| 1,11 | E | 94–118 | FVDRGWGNGCGLFGKGSLVTCAKF |
| 1,12 | E | 181–198 | LECSPRTGLDFNEMVLL |
| 1,13 | E | 202–219 | KSWLVHKQWFLDLPLPW |
| 1,14 | E | 233–271 | DLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQT |
| 1,15 | E | 276–292 | IFAGHLKCRLKMDKLT |
| 1,16 | E | 309–320 | EVAETQHGTVL |
| 1,17 | E | 363–377 | VNIEAEPPFGDSYI |
| 1,18 | E | 392–427 | KGSSIGKMFEATARGARRMAILGDTAWDFGSVGGV |
| 1,19 | E | 438–452 | FGTAYGVLFSGVSW |
| 1,20 | E | 460–471 | LLTWLGLNSRS |
| 1,21 | NS1 | 8–48 | GKELKCGSGIFVTDEVHTWTEQYKFQADSPSKLASAIQKA |
| 1,22 | NS1 | 51–70 | GVCGIRSVTRLENIMWKQI |
| 1,23 | NS1 | 111–121 | YSWKTWGKAK |
| 1,24 | NS1 | 151–170 | WEVEDYGFGVFTTNIWLKL |
| 1,25 | NS1 | 177–210 | CDHRLMSAAIKDSKAVHADMGYWIESSKNQTWQ |
| 1,26 | NS1 | 211–222 | EKASLIEVKTC |
| 1,27 | NS1 | 223–244 | WPKSHTLWSNGVLESEMIIPK |
| 1,28 | NS1 | 250–259 | SQHNYRPGY |
| 1,29 | NS1 | 260–276 | TQTAGPWHLGKLELDF |
| 1,30 | NS1 | 289–337 | CGNRGPSLRTTTASGKLIHEWCCRSCTMPPLRFRGEDGCWYGMEIRPL |
| 1,31 | NS2A | 90–104 | FLRKLTSRETALMV |
| 1,32 | NS2A | 217–272 | SWPLNEGIMAVGMVSILASALLKNDIPMTGPLVAGGLLTVCYVLSGSSADLSLEK |
| 1,33 | NS2B | 62–72 | QAEISGSSPI |
| 1,34 | NS2B | 76–91 | QQEDGSMSIKNEEEE |
| 1,35 | NS2B | 92–107 | MLTILIRTGLLVISG |
| 1,36 | NS2B | 129–141 | AGVLWDVPSPPP |
| 1,37 | NS3 | 29–40 | FGYSQIGAGVY |
| 1,38 | NS3 | 41–59 | EGVFHTMWHVTRGSVICH |
| 1,39 | NS3 | 60–84 | GGRLEPSWASVKKDLISYGGGWRL |
| 1,40 | NS3 | 87–110 | WKEGEEVQVIAVEPGKNPRAVQT |
| 1,41 | NS3 | 118–140 | TGTIGAIALDFKPGTSGSPIIN |
| 1,42 | NS3 | 141–168 | KGKVVGLYGNGVVTKSGDYVSAITQAE |
| 1,43 | NS3 | 182–321 | FRKRRLTIMDLHPGAGKTKRYLPAIVREALKRRLRTLILAPTRVVAAEMEEALRGLPIRYQTPAVKSEHTGREIVDLMCHATFTMRLLSPVRVPNYNLIIMDEAHFTDPASIAARGYISTRVGMGEAAAIFMTATPPGS |
| 1,44 | NS3 | 322–348 | DPFPQSNSPIQDEERDIPERSWNTGF |
| 1,45 | NS3 | 353–397 | FKGKTVWFVPSIKAGNDIANCLRKNGKKVIQLSRKTFDTEYQKT |
| 1,46 | NS3 | 398–465 | LNDWDFVVTTDISEMGANFRADRVIDPRRCLKPVILTDGPERVILAGPMPVTVASAAQRRGRIGRNP |
| 1,47 | NS3 | 466–557 | NENDQYIYMGQPLNNDEDHAHWTEAKMLLDNINTPEGIIPALFEPEREKSAAIDGEYRLRGEARKTFVELMRRGDLPVWLSYKVASAGISY |
| 1,48 | NS3 | 567–618 | RNNQILEENMDVEIWTKEGERKKLRPRWLDARVYSDPLALKEFKEFAAGRK |
| 1,49 | NS4A | 3–13 | NLITEMGRLP |
| 1,50 | NS4A | 20–34 | KNALDNIVMLHTTE |
| 1,51 | NS4A | 38–66 | AYQHALSELPETLETLLLLALLGAMTAG |
| 1,52 | NS4A | 98–141 | IQPHWIAASIILEFFLMVLLIPEPEKQRTPQDNQLTYVVIAIL |
| 1,53 | 2K | 22–36 | NEMGFLETTKKDLG |
| 1,54 | NS4B | 27–111 | LDVDLRPASAWTLYAVATTVLTPMLRHSIENSSVNVSLTAIANQAAVLMGLDKGWPLSKMDLGVPLLALGCYSQVNPLTLTAAV |
| 1,55 | NS4B | 115–242 | AHYAIIGPGLQAKATREAQKRTAAGIMKNPTVDGITVIDLEPIPYDPKFEKQLGQVMLLVLCVTQVLLMRTTWALCEALTLATGPITTLWEGNPGRFWNTTIAVSMANIFRGSYLAGAGLAFSLIKN |
| 1,56 | NS5 | 3–17 | QGETLGEKWKRQLN |
| 1,57 | NS5 | 26–48 | YKKSGIQEVDRTEAKEGLKRGE |
| 1,58 | NS5 | 50–70 | HHAVSRGSAKLRWFVERNLV |
| 1,59 | NS5 | 71–133 | PKGKVVDLGCGRGGWSYYCAGLKKVTEVKGYTKGGPGHEEPIPMATYGWNLVKLHSGVDVFY |
| 1,60 | NS5 | 134–171 | PPEKCDTLLCDIGESSSNPTIEEGRTLRVLKMVEPWL |
| 1,61 | NS5 | 174–190 | QFCIKVLNPYMPTVIE |
| 1,62 | NS5 | 199–243 | GGMLVRNPLSRNSTHEMYWVSNASGNIVSSVNMISRMLINRFTM |
| 1,63 | NS5 | 247–266 | ATYEKDVDLGAGTRSVSTE |
| 1,64 | NS5 | 269–282 | PDMDIIGKRIEKI |
| 1,65 | NS5 | 288–363 | SWHYDQENPYKTWAYHGSYETKQTGSASSMVNGVVKLLTKPWDVIPMVTQMAMTDTTPFGQQRVFKEKVDTRTPR |
| 1,66 | NS5 | 388–397 | PRLCTREEF |
| 1,67 | NS5 | 399–424 | KVRSNAAIGAVFTDENKWKSAREAV |
| 1,68 | NS5 | 435–518 | ERALHQEGKCETCVYNMMGKREKKLGEFGKAKGSRAIWYMWLGARFLEFEALGFLNEDHWFSRENSLSGVEGEGLHKLGYILR |
| 1,69 | NS5 | 524–548 | GGAMYADDTAGWDTRITEDDLQNE |
| 1,70 | NS5 | 564–583 | AIFKLTYQNKVVKVLRPTP |
| 1,71 | NS5 | 584–626 | GTVMDIISRKDQRGSGQVGTYGLNTFTNMEAQLIRQMEGEGV |
| 1,72 | NS5 | 650–672 | ERLKRMAISGDDCVVKPIDDRF |
| 1,73 | NS5 | 674–720 | ALTALNDMGKVRKDIPQWEPSKGWKDWQQVPFCSHHFHELIMKDGR |
| 1,74 | NS5 | 721–783 | LVVPCRNQDELIGRARISQGAGWSLRETACLGKAYAQMWSLMYFHRRDLRLAANAICSAVPV |
| 1,75 | NS5 | 784–816 | WVPTSRTTWSIHAHHQWMTTEDMLTVWNRVWI |
| 1,76 | NS5 | 817–826 | ENPWMEDKT |
| 1,77 | NS5 | 832–861 | DVPYLGKREDQWCGSLIGLTSRATWAKNI |
| 1,78 | NS5 | 878–888 | DYMPSMKRFR |
The extended block ID is composed of the peptide number (ranging from the most frequent in the given block to the least frequent), followed the block number in order of starting position from the N-terminal end of the proteome to the C-terminal end. For the extended blocks in the remaining four strings and detailed mapping of predicted T-cell epitopes, see Table S1 in Supplementary Material. The definition of the strings and the corresponding extended blocks is described in Section “Compressing Antigenic Diversity for Vaccinology Applications.”
(A) Examples of experimental evidence supporting the application of the block entropy approach to achieve broad coverage by including homologous peptide blocks in polyvalent vaccine constructs. In the four examples below, a high percentage of pan-DENV population coverage was achieved by including only blocks of peptides that have all been predicted, as well as experimentally validated, to bind HLA. Predictions for B*55:02 were done using netMHCpan 2.4 (PMID: 17726526). (B) Two examples of blocks of experimentally validated epitopes, for which the block entropy approach failed to account due to epitope predictions inconsistent with the experimental findings of the respective authors.
| Peptides | Reference | Experimental HLA | Predicted affinity (nM) | Predicted HLA | Block position | Pan-DENV peptide frequency | Protein |
|---|---|---|---|---|---|---|---|
| MLLALIAVL | 16493038 | A*02:01 | 10 | A*02:01 | 2151 | 24.86 | NS4A |
| LLLTLLATV | 16493038 | A*02:01 | 9 | A*02:01 | 2151 | 24.79 | NS4A |
| LLLGLMILL | 16493038 | A*02:01 | 14 | A*02:01 | 2151 | 23.29 | NS4A |
| MLVALLGAM | 16493038 | A*02:01 | 300 | A*02:01 | 2151 | 25.23 | NS4A |
| Accumulated frequency: | 98.17 | ||||||
| TPEGIIPSM | 7529799 | B*35:01 | 49 | B*35:01 | 1977 | 25.78 | NS3 |
| TPEGIIPTL | 7529799 | B*35:01 | 345 | B*35:01 | 1977 | 25.73 | NS3 |
| TPEGIIPAL | 7544398 | B*35 | 108 | B*35:01 | 1977 | 48.19 | NS3 |
| TPEGIIPSL | 7544398 | B*35 | 836 | B*35:01 | 1977 | 0.15 | NS |
| Accumulated frequency: | 99.85 | ||||||
| KYTDRKWCF | 16517753 | A*24 | 21 | A*24:02 | 2033 | 23.18 | NS3 |
| NYADRKWCF | 16517753 | A*24 | 32 | A*24:02 | 2033 | 7.67 | NS3 |
| QYSDRRWCF | 16517753 | A*24 | 17 | A*24:02 | 2033 | 24.89 | NS3 |
| SYKDREWCF | 16517753 | A*24 | 18 | A*24:02 | 2033 | 24.99 | NS3 |
| NYADRRWCF | 11709777 | A*24 | 23 | A*24:02 | 2033 | 17.62 | NS3 |
| Accumulated frequency: | 98.35 | ||||||
| KPWDIIPMV | 17626101 | B*55:02 | 149 | B*55:02 | 2828 | 0.04 | NS5 |
| KPWDVIPMV | 17626101 | B*55:02 | 192 | B*55:02 | 2828 | 51.09 | NS5 |
| KPWDVLPMV | 17626101 | B*55:02 | 158 | B*55:02 | 2828 | 0.30 | NS5 |
| KPWDVLPTV | 17626101 | B*55:02 | 107 | B*55:02 | 2828 | 7.53 | NS5 |
| KPWDVVPMV | 17626101 | B*55:02 | 139 | B*55:02 | 2828 | 38.73 | NS5 |
| KPWDVVPTV | 17626101 | B*55:02 | 112 | B*55:02 | 2828 | 1.65 | NS5 |
| Accumulated frequency: | 99.34 | ||||||
| FLDLPLPWT | 16493038 | A*02 | 64 | A*02:01 | 493 | 50.13 | E |
| FLDLPLPWL | 16493038 | A*02 | 11 | A*02:01 | 493 | 22.7 | E |
| FFDLPLPWT | 16493038 | A*02:01 | 13995 | A*02:01 | 493 | 23.83 | E |
| Accumulated frequency: | 96.66 | ||||||
| GTSGSPIIDKK | 12808447 | A*11 | 17 | A*11:01 | 1611 | 9.36 | NS3 |
| GTSGSPIVDRK | 12808447 | A*11 | 20 | A*11:01 | 1611 | 14.2 | NS3 |
| GTSGSPIVDKK | 12808447 | A*11 | 18 | A*11:01 | 1611 | 2.26 | NS3 |
| GTSGSPIADKK | 12808447 | A*11 | 22 | A*11:01 | 1611 | 0.04 | NS3 |
| GTSGSPIVNRE | 12808447 | A*11 | 18023 | A*11:01 | 1611 | 24.97 | NS3 |
| GTSGSPIINRE | 12808447 | A*11 | 18156 | A*11:01 | 1611 | 23.26 | NS3 |
| GTSGSPIINRK | 12808447 | A*11 | 16 | A*11:01 | 1611 | 21.53 | NS3 |
| Accumulated frequency: | 95.62 | ||||||